Last reviewed · How we verify
Tritanrix/Hiberix vaccine
Tritanrix/Hiberix is a combination vaccine that provides immunization against diphtheria, tetanus, pertussis, and Haemophilus influenzae type b through inactivated toxoids and conjugate antigens.
Tritanrix/Hiberix is a combination vaccine that provides immunization against diphtheria, tetanus, pertussis, and Haemophilus influenzae type b through inactivated toxoids and conjugate antigens. Used for Prevention of diphtheria, tetanus, pertussis, and Haemophilus influenzae type b infection in infants and children.
At a glance
| Generic name | Tritanrix/Hiberix vaccine |
|---|---|
| Also known as | DTPw-HBV/Hib vaccine |
| Sponsor | GlaxoSmithKline |
| Drug class | Combination vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains diphtheria and tetanus toxoids (inactivated bacterial toxins) that stimulate antibody production against these toxins, acellular pertussis antigens that trigger immune responses to Bordetella pertussis, and a Haemophilus influenzae type b polysaccharide conjugated to a protein carrier to enhance immunogenicity. This multi-component approach induces both humoral and cellular immunity to prevent these four serious bacterial infections.
Approved indications
- Prevention of diphtheria, tetanus, pertussis, and Haemophilus influenzae type b infection in infants and children
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Irritability or fussiness
- Drowsiness
Key clinical trials
- Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m (PHASE3)
- Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children (PHASE3)
- Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age (PHASE3)
- Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants (PHASE2)
- Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines (PHASE3)
- Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine (PHASE3)
- Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen (PHASE2)
- Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) After a Birth Dose of Hepatitis B. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tritanrix/Hiberix vaccine CI brief — competitive landscape report
- Tritanrix/Hiberix vaccine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI